Semaglutide, Tirzepatide, and the Triple Agonists: A Field Guide

Community discussion increasingly treats GLP-1-class compounds as one interchangeable category, which makes it easy to lose track of the fact that three genuinely distinct compound generations exist here, each built on a different receptor strategy.

Generation One: Single-Target GLP-1

Semaglutide activates one receptor — GLP-1 — and does so with a long enough half-life to support once-weekly dosing in the compounds built around it. It remains the most extensively studied compound in this category, with the deepest long-term human data of the three generations discussed here.

Generation Two: Dual GLP-1/GIP Agonism

Tirzepatide adds a second receptor target, GIP, alongside GLP-1. The two pathways appear to interact rather than simply stack — several studies have reported effect sizes for the dual-agonist approach that exceed what activating either receptor alone would predict, though the precise mechanism behind that interaction is still an active research question.

Generation Three: Triple Agonism

Retatrutide and related compounds add a third target, glucagon receptor activity, on top of the GLP-1/GIP combination. This is the newest and least mature evidence base of the three generations — promising early trial data, but meaningfully less long-term human evidence than either of the earlier generations.

The Comparison Question Nobody Can Fully Answer Yet

Head-to-head trials comparing all three generations directly, in the same population, over the same time horizon, are limited. Most of what gets cited as a comparison is actually two separate trials with different populations and endpoints, informally placed side by side — which is a much weaker form of evidence than it's often treated as in community discussion.

The honest field guide, then, isn't a ranking. It's three genuinely different mechanisms, at three different stages of the evidence pipeline, all still being actively studied.